Combined Intramyocardial Delivery of Human Pericytes and Cardiac Stem Cells Additively Improves the Healing of Mouse Infarcted Hearts Through Stimulation of Vascular and Muscular Repair
Authors:
- Elisa AvolioEAElisa Avolio
- Marco MeloniMMMarco Meloni
- Helen L. SpencerHSHelen L. Spencer
- Federica RiuFRFederica Riu
- Rajesh KatareRajesh Katare
- Giuseppe MangialardiGMGiuseppe Mangialardi
- Atsuhiko OikawaAOAtsuhiko Oikawa
- Iker Rodriguez-ArabaolazaIRIker Rodriguez-Arabaolaza
- Zexu DangZDZexu Dang
- Kathryn MitchellKMKathryn Mitchell
- Carlotta ReniCRCarlotta Reni
- Valeria V. AlvinoVAValeria V. Alvino
- 8 May 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 116 (10) , e81-94
Abstract
Rationale:: Optimization of cell therapy for cardiac repair may require the association of different cell populations with complementary activities. Objective:: Compare the reparative potential of saphenous vein–derived pericytes (SVPs) with that of cardiac stem cells (CSCs) in a model of myocardial infarction, and investigate whether combined cell transplantation provides further improvements. Methods and Results:: SVPs and CSCs were isolated from vein leftovers of coronary artery bypass graft surgery and discarded atrial specimens of transplanted hearts, respectively. Single or dual cell therapy (300 000 cells of each type per heart) was tested in infarcted SCID (severe combined immunodeficiency)-Beige mice. SVPs and CSCs alone improved cardiac contractility as assessed by echocardiography at 14 days post myocardial infarction. The effect was maintained, although attenuated at 42 days. At histological level, SVPs and CSCs similarly inhibited infarct size and interstitial fibrosis, SVPs were superior in inducing angiogenesis and CSCs in promoting cardiomyocyte proliferation and recruitment of endogenous stem cells. The combination of cells additively reduced the infarct size and promoted vascular proliferation and arteriogenesis, but did not surpass single therapies with regard to contractility indexes. SVPs and CSCs secrete similar amounts of hepatocyte growth factor, vascular endothelial growth factor, fibroblast growth factor, stem cell factor, and stromal cell–derived factor-1, whereas SVPs release higher quantities of angiopoietins and microRNA-132. Coculture of the 2 cell populations results in competitive as well as enhancing paracrine activities. In particular, the release of stromal cell–derived factor-1 was synergistically augmented along with downregulation of stromal cell–derived factor-1–degrading enzyme dipeptidyl peptidase 4. Conclusions:: Combinatory therapy with SVPs and CSCs may complementarily help the repair of infarcted hearts.Keywords
This publication has 42 references indexed in Scilit:
- c-kit+ cells minimally contribute cardiomyocytes to the heartNature, 2014
- Expression of concern: the SCIPIO trialThe Lancet, 2014
- Adult c-kit pos Cardiac Stem Cells Fulfill Koch’s Postulates as Causal Agents for Cardiac RegenerationCirculation Research, 2014
- Intracoronary Cardiosphere-Derived Cells After Myocardial InfarctionJACC, 2014
- Adult c-kitpos Cardiac Stem Cells Are Necessary and Sufficient for Functional Cardiac Regeneration and RepairCell, 2013
- c-kit–Positive Cardiac Progenitor CellsCirculation Research, 2013
- Enhanced Effect of Combining Human Cardiac Stem Cells and Bone Marrow Mesenchymal Stem Cells to Reduce Infarct Size and to Restore Cardiac Function After Myocardial InfarctionCirculation, 2013
- Administration of Cardiac Stem Cells in Patients With Ischemic Cardiomyopathy: The SCIPIO TrialCirculation, 2012
- Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trialThe Lancet, 2012
- RETRACTED: Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trialThe Lancet, 2011